Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen. The inclusion of Soltamox on the Medicare Part D Formulary allows broad, affordable product access to WellCare members nationwide.
DARA BioSciences CEO and chief medical officer Dr David J Drutz noted the company continues to actively pursue ways to provide physicians and patients access to our synergistic portfolio of oncology supportive care products.
"Inclusion of Soltamox on WellCare’s National Medicare Part D Formulary opens the door for DARA to a vast network, and importantly, this Part D formulary coverage allows WellCare and DARA to better address the needs of breast cancer patients on tamoxifen," Dr Drutz added.
DARA holds exclusive US marketing rights to Soltamox, the only liquid form of tamoxifen, used for the treatment and prevention of breast cancer. Soltamox offers an option to patients who may prefer or need a liquid form of tamoxifen.